Khavinson Bioregulators: The Lab, the Claims, and the Evidence

Roughly seventy short peptides, most of them two to four amino acids long, carry a single claim: that a chain this small can find a specific gene and switch it on. That claim is the foundation of the Khavinson bioregulator program, four decades of work from one institute in St. Petersburg. It runs against four decades of structural biology describing how proteins actually read DNA.

The literature is large, almost entirely Russian-language, and concentrated in a single research network. The most underreported fact about it is how rarely anyone outside that network has tested it. The first independent Western replications appeared only in 2025, and the first comprehensive functional screen of a Khavinson peptide by a non-Russian laboratory, in 2026, returned a near-null result. This review maps the program, states its central framework in its own terms, and weighs that framework against the structural biology, the regulatory record, and the evidence as it stands.

Research content. The article below summarizes published preclinical, in vitro, and Russian-language observational research literature on the Khavinson short-peptide bioregulator program. The compounds discussed are sold by Peerless Peptides for laboratory research use only and are not approved by the FDA for human or veterinary administration.

Last reviewed: June 4, 2026 by Peerless Research.

Summary

The Khavinson program proposes that very short peptides enter the cell nucleus, bind promoter DNA and histone proteins, and switch tissue-specific gene expression on or off in a sequence-specific manner. It originated in 1970s Soviet military medicine at what became the St. Petersburg Institute of Bioregulation and Gerontology (IBG), where peptide complexes were extracted from young-animal organs; the defined synthetic short peptides were derived later as standardized analogs of those extracts. The program reports approximately 775 papers and 196 patents, six Russian-registered drugs and roughly forty to sixty-four registered supplements, zero FDA approvals, and zero Western human randomized controlled trials.

The central mechanism remains biophysically unconfirmed by the methods structural biology uses to establish sequence-specific DNA recognition, and the rodent-longevity claims sit below the modern geroscience replication standard. The framework has not been falsified, and 2025 brought the first independent Western in-vitro replications of a related effect. The appropriate reading is a grade, not a verdict.

Note: The research described below was conducted in in vitro, animal-model, and Russian-language observational-cohort systems. Human safety and efficacy of these compounds have not been established. This article is a literature review, not a recommendation of use.

The Lab and the Program: IBG St. Petersburg, Not IMG Moscow

Vladimir Khavinson (1946 to 2024) directed the St. Petersburg Institute of Bioregulation and Gerontology from 1992 until his death on January 6, 2024. The program's origin, beginning around 1973, was military-medical: the extraction of more than twenty peptide complexes from animal organs, intended for the Soviet military medical service against radiation and toxic-substance injury.

The working method ran in one direction. A tissue extract was characterized in bulk, its dominant short-peptide stoichiometries were identified, and synthetic peptides matching those compositions were named as candidate active fragments. Activity-guided fractionation, the standard medicinal-chemistry route for isolating the active component of a mixture by iterative bioassay, was not the path taken.

One disambiguation is load-bearing because vendor copy erases it. The Khavinson IBG St. Petersburg program is not the Institute of Molecular Genetics (IMG) program in Moscow that produced Selank and Semax. Different city, different institute, different decade, different mechanism story. The two catalogs share no molecules in common. Grouping all of them under "Russian peptides" inherits the methodological liabilities of one program and applies them to the other, in both directions.

The two Khavinson molecules in this catalog are the tetrapeptide Epitalon (Ala-Glu-Asp-Gly) and the tripeptide Pinealon (Glu-Asp-Arg). Their dedicated literature reviews, the Epitalon literature review and the Pinealon literature review, examine each molecule in depth. This article is the program around them.

By the program's own accounting, four decades produced roughly seventy organ-specific preparations, about 775 publications, and 196 patents. The output is distributed commercially through NPCRIZ, the Saint Petersburg company that holds exclusive rights to the institute's work, across three product tiers: first-generation tissue extracts, purified extract concentrates marketed as the Cytomax line, and chemically defined synthetic short peptides marketed as the Cytogen line.

The institute holds consultative status with the United Nations, and the program's promotional materials cite a figure of more than fifteen million users across the full product range. That number is unaudited and, by the program's own description of its sales, weighted toward the registered drugs rather than the synthetic peptides that draw most Western attention.

Khavinson's death in January 2024 removed the program's central figure. His byline, or that of his immediate network, appears on the large majority of the bioregulator literature, so the loss of that node matters for how the body of work develops from here. Senior collaborators remain active at the institute, but the post-Khavinson research direction has not been publicly clarified. The program therefore reaches its moment of rising Western interest with its founder gone, its evidence base concentrated in one network, and its central mechanism still unconfirmed by laboratories outside its orbit.

The Framework: Short Peptides as Gene Regulators

The canonical statement of the framework is a 2021 systematic review in Molecules by Khavinson and colleagues^[1]. It proposes that two-to-four-residue peptides "penetrate into the nuclei and nucleoli of cells and interact with the nucleosome, the histone proteins, and both single- and double-stranded DNA," recognize sequences in gene promoters, and modulate DNA methylation. The paper assigns specific recognition motifs to specific peptides: the dipeptide Lys-Glu (Vilon) is said to bind the sequence TCGA, the tetrapeptide Lys-Glu-Asp-Trp (Pancragen) to bind a pancreatic-gene motif, and the tripeptide Glu-Asp-Arg (Pinealon) to bind the promoters of several genes. The supporting work is heavily computational and in vitro: molecular modeling, fluorescence quenching, circular dichroism, and microarray readouts.

The experimental origin of the claim is a 2011 paper from the Vanyushin laboratory, which reported that fluorescence-labeled short peptides entered the nuclei of cultured human cells and interacted in vitro with DNA oligonucleotides, with a reported preference for cytosine-containing motifs^[11]. From that starting observation the program extended the model to specific gene promoters. The 2021 review names targets across several gene families, including the antioxidant enzymes SOD2 and GPX1, the metabolic regulators PPARA and PPARG, and, for the pancreatic tetrapeptide, the differentiation factors of the insulin-producing cells. The proposed mechanism is that the peptide, once bound, shifts the methylation state of the promoter and so its transcription.

Each of these is a strong, specific, and testable claim. What kind of evidence supports them is the question the next section takes up.

The framework's status as a primary source is worth stating plainly. The 2021 review is authored by the program's own principals, and the authors themselves note that "there are very few studies in this area." It is the clearest articulation of the claim, not an independent test of it.

Why the Central Claim Runs Against Structural Biology

Sequence-specific recognition of DNA has been characterized in detail across four decades of work on yeast, fly, mouse, and human proteins. Engineered zinc-finger proteins set a quantitative baseline. Work from the Klug laboratory established that specifying a single unique site in the human genome requires an address of at least sixteen base pairs, and that recognizing such an address takes roughly six zinc-finger modules, each about thirty residues, each reading approximately three base pairs through an alpha-helix inserted into the DNA major groove and stabilized by a coordinated zinc ion (Moore, Klug and Choo, PNAS 2001; reference 9). A six-finger array runs to roughly one hundred eighty residues, and even at that size the geometry is difficult to optimize.

A two-to-four-residue peptide possesses none of that apparatus. It has no major-groove recognition helix, no metal-coordination motif, no dimerization interface, and no sixteen-to-eighteen base-pair footprint. The four-base motifs the framework assigns, sequences such as TCGA, recur many thousands of times across the genome and cannot by themselves mark a unique locus.

Fluorescence quenching, the framework's most-cited experimental method, reports that a peptide and a DNA strand come into proximity, an interaction that for a lysine-bearing peptide is largely electrostatic against the acidic phosphate backbone. It is not site-resolved, and it does not establish sequence-specific reading. In-silico docking predicts binding poses; it does not measure them.

It helps to separate the three kinds of evidence the framework rests on, because they are not interchangeable. Fluorescence quenching measures whether two molecules come close enough to transfer energy. It reports association and can estimate affinity, but it does not resolve which DNA bases the peptide touches, so it cannot establish specificity. In-silico docking generates a computational prediction of a binding pose at a named site. It is a hypothesis generator that requires experimental confirmation, not a result. Cellular gene-expression readouts after peptide exposure record an endpoint that lies far downstream of many possible causes, only one of which is direct sequence-specific DNA binding.

The framework reads agreement across these three as convergent support for the binding model. A stricter reading is that all three are equally consistent with a peptide that associates with DNA non-specifically and influences cells through routes that never require it to read a promoter.

The one peptide-DNA biophysics study from an institutional address outside the Khavinson network is a 2019 paper from Saint Petersburg State University, which examined the Glu-Asp-Arg tripeptide and DNA in the presence of mono- and divalent ions^[10]. It confirmed that an interaction occurs and characterized its ionic dependence, a pattern consistent with an electrostatic association. It did not demonstrate sequence-specific recognition under the criteria structural biology uses for that term, and its institutional reach extended within the same metropolitan research community rather than to the structural-biology groups whose verification would settle the matter.

The relevant absence is specific. In roughly fifteen years since the framework's anchor papers, no high-resolution co-crystal structure of one of these peptides bound to DNA has been deposited, and no isothermal titration calorimetry, surface plasmon resonance, or nuclear-magnetic-resonance titration confirming sequence-specific binding has been published by any laboratory.

This is an unusually long confirmation gap for a foundational mechanistic claim in a program with substantial commercial output. It is not, by itself, proof that the framework is wrong. It is a precise description of the evidence grade.

The Catalog: From Organ Extract to Defined Synthetic

The catalog is organized by source organ, and the commercial line reflects the extract-to-synthetic split. The distributor NPCRIZ markets the tissue extracts as the Cytomax line and the defined synthetic peptides as the Cytogen line. The table below covers the two carried molecules and the six synthetic and extract bioregulators most often encountered alongside them. Identity fields are drawn from PubChem and the primary literature; extracts have no single molecular identity by definition.

Compound	Type	Sequence	PubChem CID	Mol. weight	Organ framing
Epitalon	Synthetic tetrapeptide	Ala-Glu-Asp-Gly (AEDG)	219042	390.35	Pineal
Pinealon	Synthetic tripeptide	Glu-Asp-Arg (EDR)	10273502	418.41	Pineal / CNS
Vilon	Synthetic dipeptide	Lys-Glu (KE)	7010502	275.30	Thymus / immune
Vesugen	Synthetic tripeptide	Lys-Glu-Asp (KED)	87571363	390.39	Vascular
Cortagen	Synthetic tetrapeptide	Ala-Glu-Asp-Pro (AEDP)	18439621	430.41	Cortex
Pancragen	Synthetic tetrapeptide	Lys-Glu-Asp-Trp amide (KEDW)	68451868	575.6	Pancreas
Thymalin	Tissue extract	Not applicable (mixture)	Not applicable	Not applicable	Thymus
Cerluten	Tissue extract	Not applicable (mixture)	Not applicable	Not applicable	Cerebral cortex

Two identity notes correct errors that propagate widely. Pancragen is the C-terminal amide (Lys-Glu-Asp-Trp-NH2), indexed at PubChem CID 68451868; a different CID circulated by vendors, 68452887, resolves to an unrelated fluorinated small molecule and should not be used. Thymalin is a thymus extract, not the synthetic dipeptide Glu-Trp that some sources describe; that dipeptide is the separate registered drug Thymogen.

The eight compounds in the table are the ones a Western reader is most likely to meet, but they sit inside a much larger map. The catalog assigns a preparation to nearly every major organ system: Cardiogen to the heart, Bronchogen and Chonluten to the lungs, Livagen to the liver, Crystagen to the immune system, Ovagen and Testagen to the reproductive organs, Glandokort to the adrenal glands, Sigumir to cartilage, and Thyreogen to the thyroid, among others. The pattern is uniform. For each organ, an extract in the Cytomax line is paired with a defined synthetic peptide in the Cytogen line, both positioned as regulators of that specific tissue.

The breadth is itself a feature of the framework worth holding in view. A mechanism that yields a tissue-specific regulator for every organ from the same small family of two-to-four-residue sequences is a strong claim about how much biological specificity so short a peptide can carry, and it is the same claim the structural-biology section bears on.

The Regulatory Split: Two Tiers, One Brand

The single largest source of confusion in this field is the conflation of two regulatory tiers that share a brand and an inventor. Approximately six preparations hold Russian Federation drug registration, and they are predominantly the extracts: Thymalin (registration LS-000267, dated February 26, 2010), Cortexin, Epithalamin, Thymogen, Retinalamin, and Prostatilen. These carry decades of Russian clinical use. The much larger second tier, roughly forty to sixty-four preparations, is registered in Russia as biologically active food supplements. This tier contains Epitalon, Pinealon, Vesugen, Vilon, Cortagen, Pancragen, and the entire consumer Cytomax and Cytogen range. The distributor's own materials describe these consumer products as not being medicines.

In the United States, none of these is FDA-approved, and all are unapproved new drugs sold for research use only. Within the 503A compounding channel, only the two molecules that crossed into Western circulation are touched. Epitalon and Semax were placed on the FDA Category 2 do-not-compound list on September 29, 2023, and both appear on the July 23-24, 2026 Pharmacy Compounding Advisory Committee docket. Thymalin, Cortexin, Epithalamin, Pinealon, Vilon, Vesugen, Cortagen, and Pancragen are on neither the list nor the docket. On the World Anti-Doping Agency framework, none is named individually, although as non-approved substances they are plausibly captured by the S0 catch-all category.

The practical consequence is a credibility question. Marketing frequently leans on the genuine drug registration of Thymalin, Cortexin, and Epithalamin to imply equivalent validation for the synthetic supplement-tier peptides. What legitimately transfers is narrow: a shared inventor, a shared rationale, and real human safety history for the three registered extracts specifically. What does not transfer is drug-grade regulatory review, efficacy approval, or pharmaceutical quality control to the synthetics.

The Extract-Versus-Synthetic Conflation

The most consequential methodological error in the secondary literature follows directly from that two-tier structure. Clinical and observational data generated on the extracts are routinely cited as evidence for the synthetic peptides. The pattern is visible at the level of the brand pairing itself, where an extract and a synthetic are sold for the same organ system: Cerluten, a cerebral-cortex extract, alongside Pinealon, a synthetic tripeptide; Endoluten, a pineal extract, alongside Epitalon, a synthetic tetrapeptide.

The flagship case is the pineal pair. The multi-year elderly-cohort longevity data most often attached to Epitalon were generated using Epithalamin, the polydisperse bovine pineal extract, not the synthetic tetrapeptide. Epitalon is the hypothesized active fragment of that extract, not a demonstrated equivalent of it. The conflation reaches into tertiary reference works; the Alzheimer's Drug Discovery Foundation's research review notes that because the extract is an undefined, batch-variable mixture, its effects cannot be attributed solely to the synthetic peptide. The discipline this review applies is to keep extract data and synthetic-peptide data in separate evidence classes, and never to import one onto the other.

Evidence by Compound

The strength of the evidence varies across the catalog, and it is uniformly concentrated in one research network.

Thymalin holds the richest record. A 2003 cohort by Khavinson and Morozov followed 266 older adults for six to eight years and reported substantial reductions in mortality across the Thymalin and Epithalamin arms^[2]. The reported magnitudes are large, and the published account does not describe randomization, blinding, or per-arm sample sizes, so the figures warrant heavy caution. A later single-center, randomized, single-blind trial in severe respiratory illness (n=80) reported a lower in-hospital mortality in the Thymalin arm than in the control arm; it is the best-designed study in the set and remains small and within the originating network.

For the defined synthetics, the evidence is preclinical. Work in human mesenchymal-stem-cell aging cultures reported that Lys-Glu (Vilon) and Lys-Glu-Asp (Vesugen) modulated the expression of genes including IGF1, FOXO1, and NF-kB at nanomolar concentrations, with the direction of one effect reversing between two aging models^[3]. Pancragen, the pancreatic tetrapeptide, was reported to raise differentiation-factor transcripts including Pdx1 and Pax6 in pancreatic cell cultures^[4]. Cortagen, the cortical tetrapeptide derived from the Cortexin extract, was profiled by cDNA microarray in mice, where it altered roughly one and a half percent of measured transcripts^[5]. Vilon also carries rodent lifespan and oncostatic reports from the originating group^[6].

The in-vitro anchor most often cited for the synthetic peptides is a 2011 study reporting that the Glu-Asp-Arg tripeptide reduced reactive-oxygen-species accumulation and altered cell-cycle behavior in oxidatively stressed neuronal and pheochromocytoma cell lines^[12]. The reported effects sit within the range described for other short peptides bearing charged residues in similar systems, and whether they are specific to the sequence rather than to general charged-peptide chemistry has not been separated out in head-to-head work outside the program. The animal record is dominated by the Anisimov and Khavinson rodent series, which reported lifespan and tumor-incidence effects for the pineal and thymic peptides. That series is also where the tension is sharpest, because the same group's work in one mouse strain reported no mean-lifespan effect for the synthetic thymic peptide. A result that runs against the program's own narrative, produced inside the program, is a useful marker of how strain-dependent and unsettled the longevity signal remains.

Two evidentiary cautions recur. The "vascular" framing marketed for Vesugen has no peer-reviewed endothelial primary study behind it; the documented Lys-Glu-Asp literature concerns stem-cell aging and neurogenesis, not endothelial function. And Cerluten, the cerebral-cortex extract, rests on a single unblinded developer-conducted study with no indexed identifier, while several citations attached to it in marketing materials tested other substances entirely.

Research Limitations: Four Load-Bearing Critiques

First, citation concentration. The roughly 775-paper corpus originates almost entirely from Khavinson and a small co-author cluster (Anisimov, Morozov, Linkova, and the Vanyushin laboratory for the DNA-interaction work), published largely in Russian-language or low-indexing journals. Independent replication outside that orbit was effectively absent until 2025.

Second, the structural replication gap described above. The central mechanism has no confirmation by co-crystallography, calorimetry, surface plasmon resonance, or nuclear-magnetic-resonance titration.

Third, the longevity corpus sits below the modern geroscience bar. A 2024 analysis from a group including Kaeberlein and Kennedy formalized a "900-day rule": a mouse longevity claim should be held with confidence only when control median lifespan approaches roughly 900 days, because short-lived or unhealthy control colonies inflate apparent effect sizes^[7]. The single-site, often single-sex, non-blinded design of the Khavinson and Anisimov rodent lifespan studies is the failure mode that standard formalizes, and the multi-site NIA Interventions Testing Program has repeatedly failed to replicate single-lab positives held in equal regard.

Fourth, the recent independent signals cut both ways. In 2025, the first Western in-vitro replications of a related telomere effect appeared, including a study reporting telomere extension in normal cells but also documenting activation of an alternative telomere-lengthening pathway in breast-cancer cells, a safety-relevant observation absent from marketing copy^[8]. In 2026, an independent functional screen in mice tested Pinealon against established geroprotector comparators and found it safe but near-null, with only a non-significant trend on one cognitive measure while the positive controls produced clear effects. The door is open. It has not yet been walked through.

None of these critiques is a falsification of the framework. Each is a description of the evidence's current grade and reach. Assertions about cellular mechanism, animal-model effect, or human application should be weighted accordingly.

Western Reception and the Distance Between Interest and Evidence

For most of its history the program was effectively invisible to Western science. Mainstream English-language sources did not so much rebut it as ignore it. Encyclopedia coverage stayed thin, the molecules earned no entries in the major evidence-grading databases, and no laboratory funded by a Western research agency or a pharmaceutical sponsor ran a controlled experiment on any of them. Part of the reason is structural. The peptides are short, public-domain sequences with no composition-of-matter protection, so no company has a commercial incentive to fund the expensive trials that Western approval requires.

Part is linguistic, since most of the literature is Russian-language and poorly indexed. And part, since 2022, is geopolitical.

That silence began to break in 2025. Two Western in-vitro replications appeared, the more notable reporting telomere extension in normal human cells while also documenting activation of an alternative telomere-lengthening pathway in cancer cells, a finding that points in a less reassuring direction than the longevity framing and is absent from vendor copy. In 2026, the first comprehensive functional screen of a Khavinson peptide by an independent Western laboratory tested the Glu-Asp-Arg tripeptide against established geroprotector comparators in mice and returned a near-null result.

The distance between the program's reception in the biohacking community and its standing in the evidence is wide, and naming it plainly is the most useful thing this review can do. In community discussion the peptides are often treated as established longevity and cognitive agents. In the literature they are single-institution preclinical compounds whose central mechanism is unconfirmed and whose first independent tests have only just begun. Both descriptions are current at once, and the gap between them is the field's defining feature.

Regulatory Context

As of June 2026, the FDA has not evaluated any Khavinson preparation for any indication. Of the molecules adjacent to this program, only Epitalon and Semax are within the active 503A and PCAC process, both placed in Category 2 in September 2023 and both scheduled for the July 23-24, 2026 advisory-committee review. The six bioregulators surveyed here, along with Thymalin and Cortexin, are outside that process. In Russia, the regulatory tier is fixed by preparation: registered drug for the extracts named above, biologically active supplement for the synthetics. Vladimir Khavinson's death in January 2024 leaves the program's dominant author node permanently inactive, and the institute's research-direction continuity is not publicly clarified at the time of writing.

The specifics are worth stating for anyone tracking the field. The September 2023 placement of Epitalon and Semax on Category 2 designated them as substances raising significant safety concerns, which bars compounding them from bulk; the July 2026 review will weigh whether to move them toward eligibility or keep them restricted. The remaining Khavinson preparations sit outside the process because they have not entered Western circulation in the same way, not because any body has affirmatively found them safe. On the anti-doping side, none appears on the World Anti-Doping Agency list by name, but the agency's catch-all clause for substances lacking marketing authorization by any government health authority plausibly captures them, so absence from the named list is not permission. The throughline is consistent across every regulator. These are unapproved substances, lawful in the United States only as research chemicals, and the registered-drug status three of the extracts hold in Russia does not extend to the synthetic peptides or to any use beyond that country.

What Would Settle the Question

The framework is not closed, and it is worth being precise about what would open it. On the mechanism, the missing experiment is well-defined: a high-resolution structure of one of these peptides bound to a specific DNA sequence, or affinity and specificity measurements by the standard biophysical methods, produced by a laboratory outside the originating network. Any of these would move the central claim from asserted to demonstrated, or refute it. On the biology, the missing work is an independent, multi-site in-vivo study run to the standard the geroscience field applies to its own positive controls, and beyond that a registered human trial with a defined endpoint. None of this is exotic. It is the ordinary apparatus of validation that four decades of output have not yet passed through.

Until that work exists, the honest position is the one this review has held throughout. The Khavinson bioregulators are a large, internally coherent, single-institution body of preclinical and observational research advancing a specific and falsifiable mechanistic claim that has not been independently confirmed, attached to longevity and tissue-specific effects that sit below the current evidentiary bar. That is neither an endorsement nor a dismissal. It is a description of where a forty-year program stands at the moment its founder is gone and the rest of the field has finally begun to look.

References

1. Khavinson V, Popovich I, Linkova N, Mironova E, Ilina A. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. PMID: 34834147. DOI: 10.3390/molecules26227053.

2. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363.

3. Ashapkin VV, Khavinson VKh, Shilovsky GA, Linkova NS, Vanyushin BF. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. 2020;47(6):4323-4329. PMID: 32399807.

4. Khavinson VKh, Durnova AO, Polyakova VO, et al. Effects of pancragen on the differentiation of pancreatic cells during their ageing. Bull Exp Biol Med. 2013;154(4):501-504. PMID: 23486591.

5. Anisimov SV, Khavinson VKh, Anisimov VN. Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. Neuro Endocrinol Lett. 2004;25(1-2):87-93. PMID: 15159690.

6. Khavinson VKh, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000;372:261-263. PMID: 10944717.

7. Pabis K, Barardo D, Gruber J, et al. The impact of short-lived controls on the interpretation of lifespan experiments and progress in geroscience - through the lens of the "900-day rule". Ageing Res Rev. 2024;101:102512. PMID: 39332712.

8. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PMID: 40908429. DOI: 10.1007/s10522-025-10315-x.

9. Moore M, Klug A, Choo Y. Improved DNA binding specificity from polyzinc finger peptides by using strings of two-finger units. Proc Natl Acad Sci U S A. 2001;98(4):1437-1441. PMID: 11171969. DOI: 10.1073/pnas.98.4.1437.

10. Silanteva IA, Komolkin AV, Morozova EA, Vorontsov-Velyaminov PN, Kasyanenko NA. Role of mono- and divalent ions in peptide Glu-Asp-Arg-DNA interaction. J Phys Chem B. 2019;123(8):1786-1795. PMID: 30762356.

11. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. PMID: 22117547.

12. Khavinson V, Ribakova Y, Kulebiakin K, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res. 2011;14(5):535-541. PMID: 21978084.

Not intended to diagnose, treat, cure, mitigate, or prevent any disease. Sold for research, laboratory, or analytical purposes only.